Results 151 to 160 of about 1,749 (172)
Some of the next articles are maybe not open access.
Advances in the treatment of vulvovaginal atrophy
Expert Review of Obstetrics & Gynecology, 2013Vulvovaginal atrophy is a frequently neglected symptom of menopause. While an estimated 10–40% of women are affected by the progressive symptoms of vaginal dryness, irritation, itching, dysuria and dyspareunia, only a quarter of symptomatic women are believed to seek medical attention. Until recently, treatments for vulvovaginal atrophy were limited to
Zoe R. Belkin +2 more
openaire +2 more sources
Ospemifene, vulvovaginal atrophy, and breast cancer
Maturitas, 2013The incidence and severity of vulvovaginal atrophy (VVA) in postmenopausal breast cancer patients has a significant impact on quality of life. While the etiology of VVA is primarily related to low estrogen levels seen in menopause, women with breast cancer have an added risk of VVA induced by a combination of chemotherapy, hormonal therapy, and ...
Gregory T. Wurz +2 more
openaire +3 more sources
Prasterone: A Review in Vulvovaginal Atrophy
Drugs & Aging, 2019Vulvovaginal atrophy (VVA) is a progressive condition commonly seen in postmenopausal women. The cessation of ovarian estrogen secretion and a fall in serum levels of dehydroepiandrosterone (DHEA), the remaining source of estrogens and androgens, are thought to promote the development of VVA in this population. Intravaginal prasterone (Intrarosa®) is a
openaire +3 more sources
Current treatment options for vulvovaginal atrophy
Expert Review of Obstetrics & Gynecology, 2011Vulvovaginal atrophy (VVA), a condition associated with declining estrogen levels, is commonly seen in postmenopausal women. VVA is marked by vaginal dryness, itching, dyspareunia and incontinence, which can contribute to diminishing quality of life for millions of postmenopausal women worldwide.
Michael W. DeGregorio, Rebekah A. Burich
openaire +2 more sources
Managing vulvovaginal atrophy after breast cancer
Post Reproductive Health, 2018Cancer treatment may result in loss of ovarian function through surgical removal of the ovaries, chemotherapy or radiation. While menopausal symptoms, such as hot flushes, night sweats, sleep disturbance, memory concerns and mood issues can be extremely bothersome to some women going through menopause naturally, women who undergo an induced menopause ...
Mary Ann Lumsden +9 more
openaire +3 more sources
[Sulphurous vaginal douching and vulvovaginal atrophy].
La Clinica terapeutica, 2017During climacteric the reduction or interruption of estrogenic stimulus determines a gradual atrophy of the tissues of the urogenital tract.Vulvovaginal atrophy can be cause of dryness, itch, burning, and dyspareunia. Vulvovaginal atrophy is associated also with depression.
Amelia Filippelli +4 more
openaire +2 more sources
Menopause, 2020
Abstract Objective: To estimate the impact of vulvovaginal atrophy (VVA) on sexual function in a clinical population of postmenopausal women. Methods: Women 45 to 75 years old and more than 12 months after the last menstruation, who attended menopausal/gynecological ...
Rossella E. Nappi +5 more
openaire +4 more sources
Abstract Objective: To estimate the impact of vulvovaginal atrophy (VVA) on sexual function in a clinical population of postmenopausal women. Methods: Women 45 to 75 years old and more than 12 months after the last menstruation, who attended menopausal/gynecological ...
Rossella E. Nappi +5 more
openaire +4 more sources
Ospemifene for the Treatment of Vulvovaginal Atrophy and Dyspareunia in Postmenopausal Women
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014Vulvovaginal atrophy (VVA) and dyspareunia are common problems experienced by postmenopausal women, although few seek treatment. Symptom-based therapies include nonhormonal vaginal lubricants, vaginal moisturizers, low-dose vaginal estrogen, and systemic estrogen.
Valerie B. Clinard +3 more
openaire +3 more sources
A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy
Menopause, 2018Abstract Objectives: Intravaginal testosterone has emerged as a potential treatment for vulvovaginal atrophy (VVA) in women, in general, and women taking an aromatase inhibitor (AI). A systematic review of the literature was undertaken to determine whether available clinical trial data support efficacy and safety of ...
Robin J. Bell +3 more
openaire +3 more sources
Laser Treatment for Vulvovaginal Atrophy
2019Laser therapy has a therapeutic role for different medical conditions and most recently has gained interest as a non-hormonal treatment for vulvovaginal atrophy or genitourinary syndrome of menopause (GSM). Both microablative fractional CO2 laser and the second-generation non-ablative vaginal Er:YAG laser (VEL) can alleviate the symptoms of dryness and
openaire +2 more sources